EPRX:TSX, Eupraxia Pharmaceuticals Inc.
EPRX stock overview
Eupraxia Pharmaceuticals Inc. (EPRX:TSX) closed at $9.45 on October 15, 2026,
up 0.96% on the day.
The stock trades 27.8% below its 52-week high of $13.08
and 28.6% above its 52-week low of $7.35.
Over the past year, it gained 10.4%.
Eupraxia Pharmaceuticals Inc. is part of the Health Care sector.
Key figures
- Price
- $9.45
- Day change
- +0.96%
- Volume
- 34,011
- Average volume
- 75,464
- Market cap
- 624M+
- 52-week range
- $7.35 – $13.08
- 50-day average
- $10.46
- 200-day average
- $10.22
Performance
| 5D |
1M |
3M |
6M |
1Y |
| -2.40% |
-16.43% |
+0.97% |
-5.45% |
+10.38% |
Price action over the past year
In 252 trading sessions since October 14, 2025, EPRX closed higher on 113 days (45%).
Its best day was September 2, 2026 (+17.18%) and its worst was October 1, 2026 (-13.86%).
The stock moved 10% or more in a single session 7 times.
It opened at least 5% above the previous day's high 2 times.
Recent signals
EPRX news
-
Oct 15, 2026:
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
-
Oct 9, 2026:
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
-
Sep 30, 2026:
Eupraxia Says Resolve Trial Updated Data Suggest Annual Dosing Possible in EoE Patients
-
Sep 30, 2026:
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
-
Sep 12, 2026:
Eupraxia Pharma (EPRX): When Painful Swallowing Nearly Disappeared, Investors Took Notice
-
Sep 8, 2026:
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences
-
Aug 13, 2026:
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
-
Aug 11, 2026:
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
About Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to approved drugs. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. Its lead product candidate, EP-104IAR, is in development for the treatment of pain due to osteoarthritis of the knee. In addition, it is developing a pipeline of earlier-stage long-acting formulations.
Find more stocks like EPRX with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.